Close

Research Insight

Bayer collaborates with US NSAB Project Investigate Additional Adjuvant Therapy in Colon Cancer

Bayer and the U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP), a leading clinical trials cooperative group, are collaborating on a new Phase III study to investigate Stivarga® (regorafenib) as an additional adjuvant therapy in colon cancer.The ARGO...

Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated wi

Following the recommendation of an independent Data Monitoring Committee (DMC), Bayer is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) with immediate effect. The DMC is an independent committee...

Edwards Lifesciences’ Philanthropy Impacts 200,000 Underserved Patients Through Every Heartbeat Matt

Edwards Lifesciences Corporation the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that reports from its philanthropic partners in the Every Heartbeat Matters initiative demonstrate they have impacted the global burden of...

Horizon Discovery Introduces High Throughput Platform for Immuno-Oncology Research

Horizon Discovery Group plc, the world leader in the application of gene editing technologies including custom screening and specialized assay services,today announced the launch of a new platform for immuno-oncology research. The platform consists of several high throughput assays...

IMS Health Study: U.S Drug Spending Growth Reaches 8.5 Percent in 2015

According to a new report issued by the IMS Institute for Healthcare Informatics. The surge of new medicines remained strong last year and demand for recently launched brands maintained historically high levels. The savings from branded medicines facing generic...

IMS Health Study: U.S. Drug Spending Growth Reaches 8.5 Percent in 2015

According to a new report issued by the IMS Institute for Healthcare Informatics. The surge of new medicines remained strong last year and demand for recently launched brands maintained historically high levels. The savings from branded medicines facing generic...

Proton Therapy Center Initiates 3d Image Guided Proton Therapy To Enhance Precision Of Cancer Care

Varian Medical Systems (NYSE: VAR), today announced that its 3D volumetric imaging technology is now being used at a California proton therapy center to enhance the precision and quality of its treatments for cancer patients.  The treatments with image-guided...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read